(2R)-3,3,3-trifluoro-2-hydroxy-2-methyl-1-[(3R)-3-methyl-4-(3,4,5-trimethoxybenzoyl)piperazin-1-yl]propan-1-one
C19H25F3N2O6 — CID 10788941
Data last refreshed: (MolForge compound catalog, from PubChem)
About (2R)-3,3,3-trifluoro-2-hydroxy-2-methyl-1-[(3R)-3-methyl-4-(3,4,5-trimethoxybenzoyl)piperazin-1-yl]propan-1-one
(2R)-3,3,3-trifluoro-2-hydroxy-2-methyl-1-[(3R)-3-methyl-4-(3,4,5-trimethoxybenzoyl)piperazin-1-yl]propan-1-one (PubChem CID 10788941) has the molecular formula C19H25F3N2O6 and a molecular weight of 434.41 g/mol. Its IUPAC name is (2R)-3,3,3-trifluoro-2-hydroxy-2-methyl-1-[(3R)-3-methyl-4-(3,4,5-trimethoxybenzoyl)piperazin-1-yl]propan-1-one.
Molecular Properties
| Compound Name | (2R)-3,3,3-trifluoro-2-hydroxy-2-methyl-1-[(3R)-3-methyl-4-(3,4,5-trimethoxybenzoyl)piperazin-1-yl]propan-1-one |
|---|---|
| PubChem CID | 10788941 |
| Molecular Formula | C19H25F3N2O6 |
| Molecular Weight | 434.41 g/mol |
| Exact Mass | 434.17 |
| IUPAC Name | (2R)-3,3,3-trifluoro-2-hydroxy-2-methyl-1-[(3R)-3-methyl-4-(3,4,5-trimethoxybenzoyl)piperazin-1-yl]propan-1-one |
| SMILES | COc1cc(C(=O)N2CCN(C(=O)[C@@](C)(O)C(F)(F)F)C[C@H]2C)cc(OC)c1OC |
| InChI | InChI=1S/C19H25F3N2O6/c1-11-10-23(17(26)18(2,27)19(20,21)22)6-7-24(11)16(25)12-8-13(28-3)15(30-5)14(9-12)29-4/h8-9,11,27H,6-7,10H2,1-5H3/t11-,18-/m1/s1 |
| InChIKey | UGXPDIGRDIXCGO-ADLMAVQZSA-N |
| XLogP | 1.70 |
| TPSA | 88.54 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 30 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 434.41 |
| LogP ≤ 5 | 1.70 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 10788941 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.